DXC 600: cost and payments to doctors
What Medicare Part D paid pharmacies for DXC 600, and the payments that named it as the associated device or medical supply under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Beckman Coulter, Inc.?
Beckman Coulter, Inc. reported the most payments naming DXC 600. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $220K
- Providers
- 0
- Transactions
- 25
- Average per transaction
- $8,780
The per-transaction average — $8,780 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. No payment naming this product was reported to an individual clinician. The Sunshine Act also covers payments to teaching hospitals as institutions — research funding, grants and device loans — and for this product that is all of it.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Beckman Coulter, Inc. | $219,509 | 100.0% |
Other products from Beckman Coulter, Inc.
The company that reported the most payments naming DXC 600 also reports against these.
- CYTOFLEX$23,654,772
- NAVIOS$23,419,352
- ACCESS 2$15,912,764
- UNICEL DXI ACCESS$15,875,474
- AQUIOS$14,335,683
- Cytomics FC500$14,335,087
- AQUIOS CL$9,319,428
- FC 500 SERIES$9,317,514
- DXI 9000 Access Immunoassay Analyzer$315,744
- DXC 800$219,509